1.21
price down icon3.20%   -0.04
after-market Handel nachbörslich: 1.21
loading
Schlusskurs vom Vortag:
$1.25
Offen:
$1.24
24-Stunden-Volumen:
210.51K
Relative Volume:
0.41
Marktkapitalisierung:
$74.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-73.79M
KGV:
-0.6576
EPS:
-1.84
Netto-Cashflow:
$-77.44M
1W Leistung:
-1.63%
1M Leistung:
+16.35%
6M Leistung:
-39.80%
1J Leistung:
-67.47%
1-Tages-Spanne:
Value
$1.20
$1.246
1-Wochen-Bereich:
Value
$1.195
$1.25
52-Wochen-Spanne:
Value
$0.8332
$5.3899

Pyxis Oncology Inc Stock (PYXS) Company Profile

Name
Firmenname
Pyxis Oncology Inc
Name
Telefon
(617) 221-9059
Name
Adresse
321 HARRISON AVENUE, BOSTON
Name
Mitarbeiter
44
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-11
Name
Neueste SEC-Einreichungen
Name
PYXS's Discussions on Twitter

Vergleichen Sie PYXS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PYXS
Pyxis Oncology Inc
1.21 76.20M 0 -73.79M -77.44M -1.84
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-21 Herabstufung William Blair Outperform → Mkt Perform
2024-11-08 Eingeleitet Stephens Overweight
2024-08-08 Eingeleitet Stifel Buy
2024-05-07 Fortgesetzt Jefferies Buy
2024-02-09 Eingeleitet BTIG Research Buy
2024-01-23 Eingeleitet Leerink Partners Outperform
2023-09-05 Eingeleitet RBC Capital Mkts Outperform
2021-11-02 Eingeleitet BofA Securities Neutral
2021-11-02 Eingeleitet Credit Suisse Outperform
2021-11-02 Eingeleitet Jefferies Buy
Alle ansehen

Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten

pulisher
03:30 AM

Northern Trust Corp Sells 15,449 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World

03:30 AM
pulisher
May 30, 2025

Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments - TipRanks

May 30, 2025
pulisher
May 29, 2025

Millennium Management LLC Has $4.65 Million Stock Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World

May 29, 2025
pulisher
May 25, 2025

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Consensus PT from Analysts - Defense World

May 25, 2025
pulisher
May 22, 2025

Q2 EPS Estimates for Pyxis Oncology Cut by HC Wainwright - Defense World

May 22, 2025
pulisher
May 22, 2025

HC Wainwright Weighs in on Pyxis Oncology Q1 Earnings - Defense World

May 22, 2025
pulisher
May 20, 2025

Leerink Partnrs Comments on Pyxis Oncology FY2029 Earnings - Defense World

May 20, 2025
pulisher
May 19, 2025

Pyxis Oncology (PYXS) Receives Reiterated Buy Rating from Analys - GuruFocus

May 19, 2025
pulisher
May 18, 2025

Dimensional Fund Advisors LP Raises Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World

May 18, 2025
pulisher
May 16, 2025

Pyxis Oncology : May 2025 Corporate Deck (9474da) - marketscreener.com

May 16, 2025
pulisher
May 15, 2025

Pyxis Oncology Reports Q1 Loss and Business Update - TipRanks

May 15, 2025
pulisher
May 15, 2025

Pyxis Oncology (PYXS) Advances Cancer Treatment Research | PYXS Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Pyxis Oncology, Inc. SEC 10-Q Report - TradingView

May 15, 2025
pulisher
May 15, 2025

Pyxis Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2025
pulisher
May 15, 2025

Pyxis Oncology : May 2025 Corporate Deck (c8a9bd) - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Barclays PLC Purchases 12,924 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World

May 15, 2025
pulisher
May 14, 2025

Pyxis Oncology to Participate in Two Upcoming Investor Conferences - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Pyxis Oncology, Inc. CEO Lara S. Sullivan to Participate in Upcoming Investor Conferences - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Next-Gen Cancer Drug Developer Pyxis Oncology Sets Major Investor Conference Schedule for May-June - Stock Titan

May 14, 2025
pulisher
May 11, 2025

Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 07, 2025

New Approaches to Tumor Targeting Are Driving the Next Wave of Oncology Breakthroughs - Baystreet.ca

May 07, 2025
pulisher
May 04, 2025

Renaissance Technologies LLC Acquires 133,018 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World

May 04, 2025
pulisher
May 01, 2025

Pyxis Oncology Inc (PYXS) is a good investment, but the stock may be overvalued - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Taking a look at what insiders are doing to gauge the Pyxis Oncology Inc (PYXS)’s direction - knoxdaily.com

May 01, 2025
pulisher
Apr 25, 2025

Pyxis Oncology reveals promising preclinical data for cancer drug - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

Pyxis Oncology reveals promising preclinical data for cancer drug By Investing.com - Investing.com UK

Apr 25, 2025
pulisher
Apr 25, 2025

Pyxis Oncology Highlights Promising Preclinical Data for Micvotabart Pelidotin (MICVO) in Cancer Therapy at AACR 2025 - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC - TradingView

Apr 25, 2025
pulisher
Apr 25, 2025

Novel Cancer Drug Shows 91% Tumor Inhibition in Breakthrough Study | PYXS Stock News - Stock Titan

Apr 25, 2025
pulisher
Apr 24, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research

Apr 24, 2025
pulisher
Apr 24, 2025

Pyxis Oncology Inc (PYXS) requires closer examination - uspostnews.com

Apr 24, 2025
pulisher
Apr 23, 2025

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Pyxis Oncology Inc (PYXS) receives a Mkt perform rating from William Blair - knoxdaily.com

Apr 23, 2025
pulisher
Apr 22, 2025

Pyxis Oncology Inc (PYXS) Stock: A Year of Highs and Lows in the Market - investchronicle.com

Apr 22, 2025
pulisher
Apr 17, 2025

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

Apr 17, 2025
pulisher
Apr 16, 2025

Top Cancer Stocks to Buy to Boost Your Portfolio's Health - Yahoo Finance

Apr 16, 2025
pulisher
Apr 15, 2025

Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace

Apr 15, 2025
pulisher
Apr 13, 2025

Sei Investments Co. Acquires New Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

American Century Companies Inc. Has $468,000 Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World

Apr 13, 2025
pulisher
Apr 08, 2025

Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS) - marketscreener.com

Apr 08, 2025
pulisher
Apr 07, 2025

Pyxis Oncology stock plunges to 52-week low of $0.86 - Investing.com Australia

Apr 07, 2025
pulisher
Apr 02, 2025

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

CEO Spotlight: Pyxis Oncology to Reveal Latest Cancer Drug Strategy at Elite Stifel Forum - Stock Titan

Apr 02, 2025
pulisher
Mar 31, 2025

Pyxis Oncology stock hits 52-week low at $0.98 amid downturn - Investing.com Canada

Mar 31, 2025
pulisher
Mar 26, 2025

Is it possible to buy Pyxis Oncology Inc(PYXS) shares at a good price now? - US Post News

Mar 26, 2025
pulisher
Mar 26, 2025

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - The Manila Times

Mar 26, 2025
pulisher
Mar 25, 2025

Pyxis Oncology to Present Preclinical Data for Micvo Cancer Drug Candidate - MarketScreener

Mar 25, 2025

Finanzdaten der Pyxis Oncology Inc-Aktie (PYXS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):